The heart, an organ with a continuously high demand for energy, inherently lacks substantial reserves. The precise mechanisms that prioritize energy allocation to cardiac mitochondria, ensuring steady-state ATP production amidst high-energy organs, remain poorly understood. Our study sheds light on this process by identifying a two-strata flux system driven by the starvation hormone FGF21. We demonstrate that systemic disruptions in interorgan metabolite mobilization and transcardiac flux, arising from either adipose lipolysis or hepatic ketogenesis due to FGF21 deficiency, directly impair cardiac energetic performance. Locally, this impairment is linked to compromised intracardiac utilization of various metabolites via ketolysis and oxidation pathways, along with hindered mitochondrial biogenesis, TCA cycle, ETC flow, and OXPHOS. Consequently, the heart shifts to a hypometabolic, glycolytic, and hypoenergy state, with a reduced capacity to cope with physiological stressors such as fasting, starvation, strenuous exercise, endurance training, and cold exposure, leading to a diminished heart rate, contractility, and hemodynamic stability. Pharmacological or genetic restoration of FGF21 ameliorates these defects, reenergizing stress-exhausted hearts. This hierarchical energy-prioritizing mechanism is orchestrated by the LKB1-AMPK-mTOR energy stress response pathways. Disrupting cardiac LKB1 or mTOR pathways, akin to stalling mitochondrial energy conduits, obstructs the FGF21-governed cardiac energetic potential. Our findings reveal an essential two-strata energy flux system critical for cardiac energetic efficiency regulated by FGF21, which spatiotemporally optimizes interorgan and transcardiac metabolite flux and intracardiac mitochondrial energy sufficiency. This discovery informs the design of strategies for treating cardiac diseases linked to mitochondrial or energy deficiencies.
A two-strata energy flux system driven by a stress hormone prioritizes cardiac energetics.
由应激激素驱动的双层能量通量系统优先考虑心脏能量
阅读:11
作者:Rao Zhiheng, Chen Zhichao, Bao Yuxuan, Lu Zhenzhen, Tang Yuli, Zhu Jiamei, Ma Jianjia, Dong Siyang, Shi Jiawei, Sheng Suhui, Chen Yajing, Wang Jiaojiao, Mukondiwa Alan Vengai, Li Ziyue, Wang Xulan, Huang Zibo, Li Chi, Ding Wumengwei, Chen Mengjie, Han Ziyi, Wang Cong, Pan Xuebo, Wang Xiaojie, Zhu Hong, Lin Li, Huang Zhifeng, Lu Weiqin, Li Xiaokun, Luo Yongde
| 期刊: | Signal Transduction and Targeted Therapy | 影响因子: | 52.700 |
| 时间: | 2025 | 起止号: | 2025 Sep 26; 10(1):315 |
| doi: | 10.1038/s41392-025-02402-9 | 研究方向: | 心血管 |
特别声明
1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。
2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。
3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。
4、投稿及合作请联系:info@biocloudy.com。
